Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Charité – Universitätsmedizin Berlin, Germany

In this page

How to contact the center

Full member

HCP Center

In addition to its role in research and teaching, the Hospital's fundamental mission also includes the care and treatment of patients. With 655.138 outpatient cases and 132.383 inpatient cases a year, Charité treats more patients than any other university hospital in Germany and, as a result, is able to draw on a wealth of experience and expertise.

As a tertiary care institution, Charité is able to offer treatments for a diverse range of medical conditions. The hospital comprises approximately 100 different clinics and departments covering the entire spectrum of modern medicine. From allergy and immunology to vascular surgery, our diagnostic and treatment options set a benchmark for other health care providers.

Picture : INTERRAILS, CC BY-SA 4.0, via Wikimedia Commons

Contact

Charité – Universitätsmedizin Berlin, Germany

Charitépl. 1
10117 Berlin
Germany

Team

Pr Paul Friedemann

Representative

Germany

Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8)
See more

Dr Judith Bellmann-Strobl

Substitute

Germany

See more

Dr Frederike Oertel

Germany

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)
See more

Clinical trials

NCT05566795 - Recruiting, Active

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Interventional
See the trial
voir la fiche

NCT05063162 - Recruiting, Active

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)

Interventional
See the trial
voir la fiche
NCT05271409 - Recruiting, Active

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab As Monotherapy Or In Addition To Baseline Therapy In Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Interventional
See the trial
voir la fiche
NCT05987423 - Recruiting, Active

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Moderate-To-Severe Thyroid Eye Disease

Interventional
See the trial
voir la fiche
NCT05811351 - Recruiting, Active

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Interventional
See the trial
voir la fiche
NCT04270747 - Completed

A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration

Interventional
See the trial
voir la fiche
NCT05384249 - Recruiting, Active

A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Interventional
See the trial
voir la fiche
DRKS00023562 - Recruiting, Active

Evaluation of the effectiveness of transcorneal electrostimulation in patients with retinitis pigmentosa - a multicenter, prospective, randomized, controlled and double-blind study on behalf of the G-BA

Interventional
See the trial
voir la fiche